Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Early work revealed that TFEB is highly effective in ameliorating tau/NFT pathology and rescuing cognitive impairment and neurodegeneration. TFEB targets only the aberrant tau species and this ...